Abstract:The objectives of the present study were to investigate the effect of ANG-(1-7) on the development of cardiac hypertrophy and to identify the intracellular mechanism underlying this action of ANG-(1-7). Blood pressure and heart rate were recorded using radiotelemetry before and after chronic subcutaneous infusion of control (PBS), ANG II, ANG-(1-7), or ANG II + ANG-(1-7) for 4 wk in normotensive rats. Chronic administration of ANG-(1-7) did not affect either basal blood pressure or the ANG II-induced elevation in blood pressure. However, ANG-(1-7) significantly attenuated ANG II-induced cardiac hypertrophy and perivascular fibrosis in these rats. These effects of ANG-(1-7) were confirmed in cultured cardiomyocytes, in which ANG-(1-7) significantly attenuated ANG II-induced increases in cell size. This protective effect of ANG-(1-7) was significantly attenuated by pretreatment with A779 (a Mas receptor antagonist) or Mito-TEMPO (a mitochondria-targeting superoxide scavenger) as well as blockade of Sirt3 (a deacetylation-acting protein) by viral vector-mediated overexpression of sirtuin (Sirt)3 short hairpin (sh)RNA. Western blot analysis demonstrated that treatment with ANG-(1-7) dramatically increased Sirt3 expression. In addition, ANG-(1-7) attenuated the ANG II-induced increase in mitochondrial ROS generation, an effect that was abolished by A779 or Sirt3 shRNA. Moreover, ANG-(1-7) increased FoxO3a deacetylation and SOD2 expression, and these effects were blocked by Sirt3 shRNA. In summary, the protective effects of ANG-(1-7) on ANG II-induced cardiac hypertrophy and increased mitochondrial ROS production are mediated by elevated SOD2 expression via stimulation of Sirt3-dependent deacetylation of FoxO3a in cardiomyocytes. Thus, activation of the ANG-(1-7)/Sirt3 signaling pathway could be a novel therapeutic strategy in the management of cardiac hypertrophy and associated complications.NEW & NOTEWORTHY Chronic subcutaneous ANG-(1-7) has no effect on ANG II-induced elevations in blood pressure but significantly attenuates ANG II-induced cardiac hypertrophy and fibrosis by a mitochondrial ROS-dependent mechanism. This protective effect of ANG-(1-7) against the action of ANG II action is mediated by stimulation of sirtuin-3-mediated deacetylation of FoxO3a, which triggers SOD2 expression.

Syringin Prevents Cardiac Hypertrophy Induced by Pressure Overload Through the Attenuation of Autophagy

Syringic acid mitigates isoproterenol‐induced cardiac hypertrophy and fibrosis by downregulating Ereg

Shensongyangxin protects against pressure overload‑induced cardiac hypertrophy

Syringin exerts anti‐inflammatory and antioxidant effects by regulating SIRT1 signaling in rat and cell models of acute myocardial infarction

The study of glycyrrhizin effects in cardiac hypertrophy and its possible mechanisms

Apigenin Attenuates Transverse Aortic Constriction-Induced Myocardial Hypertrophy: The Key Role of miR-185-5p/SREBP2-Mediated Autophagy

Naringenin Attenuates Pressure Overload-Induced Cardiac Hypertrophy.

Silibinin Attenuates Cardiac Hypertrophy and Fibrosis Through Blocking EGFR‐dependent Signaling

Angiotensin-(1-7) Attenuates Angiotensin II-induced Cardiac Hypertrophy Via a Sirt3-dependent Mechanism.

Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative Stress

GW24-e3170 Angiotensin-(1-7) Downregulates Angiotensin II Type 1 Receptor and Inhibites Mechanical Stress-Induced Cardiomyocyte Autophagy

QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats

Inhibiting glycosphingolipids alleviates cardiac hypertrophy by reducing reactive oxygen species and restoring autophagic homeostasis

Puerarin Attenuates Pressure Overload-Induced Cardiac Hypertrophy.

Synergistic cardiac pathological hypertrophy induced by high-salt diet in IGF-IIRα cardiac-specific transgenic rats

Stem Cell Antigen 1 Protects Against Cardiac Hypertrophy And Fibrosis After Pressure Overload

Angiotensin-converting Enzyme Inhibitory Peptide Attenuates Cardiac Hypertrophy Associated with ACE2/Ang (1-7)/Masr Axis and PKC81 Pathway

Andrographolide Protects against Aortic Banding-Induced Experimental Cardiac Hypertrophy by Inhibiting MAPKs Signaling

Synaptotagmin-7 mediates cardiac hypertrophy by targeting autophagy

Arctiin Protects Against Cardiac Hypertrophy Through Inhibiting MAPKs and AKT Signaling Pathways.

Sanguinarine Protects Against Pressure Overload-Induced Cardiac Remodeling Via Inhibition Of Nuclear Factor-Kappa B Activation